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Bcl-xLIntegrin signaling is comprised of well-characterized pathways generally involved in cell survival. α9β1 integrin
has recently become a target of study and has been shown to present pro-survival effects on neutrophils.
However, there are no detailed studies on howα9β1 integrin-coupled signaling pathways interact and how they
converge to ﬁnally modulate spontaneous apoptosis in neutrophils. In this regard we sought to investigate the
main signaling events triggered by α9β1 integrin engagement and how these signaling pathways modulate the
apoptotic programof human neutrophils. Using VLO5, a snake venom disintegrin shown to bind toα9β1 integrin
in neutrophils, we demonstrate that α9β1 integrin engagement leads to the activation of integrin signaling
pathways and potently reduces neutrophil spontaneous apoptosis. These effects are dependent on the activation
of PI3K and MAPK pathways, since both LY294002 (PI3K inhibitor) or PD95059 (MEK inhibitor) reverted the
effects of VLO5/α9β1 interaction. Moreover we show that VLO5/α9β1 engagement induces NF-κB nuclear
translocation and increases the ratio between anti- and pro-apoptotic proteins by inducing the degradation of
pro-apoptotic protein Bad and increasing the expression of anti-apoptotic protein Bcl-xL. VLO5 also inhibited the
early steps of neutrophil spontaneous apoptosis by preventing Bax translocation to the outer mitochondrial
membrane and consequent cytochrome c release. In conclusion, as the mechanistic details of α9β1 integrin
signaling pathways inhumanneutrophils becomes clearer, it shouldbecomepossible to develop new therapeutic
agents for human diseases where neutrophils play a prominent role.ase; ECM, extracellular matrix;
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During recruitment from circulation and throughout their migration
towards sites of inﬂammation, neutrophils (PMNs) receive molecular
cues from their surrounding environment that concomitantly expand
their short life span and activate a series of molecular effector
mechanisms. Together these cues promote the arrival of viable, fully
competent cells that are fundamental for host protection by their
capacity for ingesting and killing invading microorganisms [1,2].
Integrins mediate many of the PMN–endothelial cell and PMN–
extracellular matrix (ECM) interactions that occur during PMNrecruitment and migration. Therefore integrins represent an important
source of signals received by PMNs throughout their exit from
circulation and arrival into tissues [2,3]. PMN integrins can either be
constitutively expressed (αLβ2, αMβ2, αvβ3 and α9β1) or upregulated
upon activation (α2β1, α3β1, α4β1 and α5β1). Moreover some
constitutively expressed integrins, such asα9β1 integrin, can be further
upregulated upon stimulation [4]. The α9β1 integrin is widely
distributed in the human body and is expressed in airway epithelium,
endothelial cells, hepatocytes, muscle cells and PMNs [5,6]. Multiple
endogenous ligands have been identiﬁed for this integrin, including the
inducible endothelial counter-receptor, vascular cell adhesion mole-
cule-1 (VCAM-1) [7], and the extracellularmatrix proteins tenascin C [8]
and osteopontin [9]. This integrin was also shown to interact with
ADAM (a disintegrin and metalloprotease) family members such as
ADAM12 and ADAM15 through their disintegrin-like domain [10,11].
On PMNs the integrinα9β1 is highly expressed and critical for adhesion
and transendothelialmigration through its interactionwithVCAM-1 [7].
Integrin-coupled signaling events are generally initiated by
activation of focal adhesion kinase (FAK). FAK is a non-receptor
tyrosine kinase that upon activation can serve as a docking site for
several signaling proteins such as c-Src, phosphatydylinositol-3-
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14]. Integrin-mediated cell adhesion and FAK activation can also
activate the Ras/Raf/MAPK pathway in leukocytes including extra-
cellular signal-regulated kinase (Erk) 1/2, c-Jun kinase (JNK), and p38
[15,16]. Activation of both PI3K and MAPK pathways in PMNs is
largely associated with delayed spontaneous apoptosis. In fact,
activation of integrin-coupled signaling pathways triggers intracellu-
lar events that are shared with classical anti-apoptotic signals. For
example, granulocyte macrophage colony-stimulating factor (GM-
CSF) delays PMN spontaneous apoptosis through the activation of
PI3K and Erk [17], a signaling pathway also triggered by integrin
engagement [18-20]. Moreover integrin engagement leads to activa-
tion and nuclear translocation of nuclear factor-κB (NF-κB) [21-23] an
event triggered by cytokines and associated with inhibition of PMN
apoptosis [24,25]. Further support for these ﬁndings comes from in
vitro and in vivo studies showing that PMN-endothelial cell and PMN-
ECM interactions mediated by integrins interfere with PMN life span,
delaying their spontaneous apoptosis [26,27].
A recent study demonstrated that in PMNs mitochondria serves
exclusively as a mediator of apoptosis [28]. The mitochondrial
apoptotic pathway is initiated by translocation of pro-apoptotic
proteins such as Bax from the cytosol to themitochondrial membrane.
Insertion of pro-apoptotic proteins onmitochondrial membrane leads
to the release of cytochrome c (cyt c) from the mitochondria to the
cytosol. Free cyt c associates with APAF-1 and triggers the assembly
and activation of apoptosome, an event that culminates with the
activation of caspase-9 and -3 [29,30]. Activation of the mitochondrial
apoptotic pathway in PMNs can bemodulated by upregulation of anti-
apoptotic proteins such as Bcl-xL. These anti-apoptotic proteins
interact with pro-apoptotic proteins and prevent their insertion on
mitochondrial membranes [30]. Synthesis of anti-apoptotic proteins
in PMNs occurs in response to cytokines and other anti-apoptotic
stimuli mainly through the activation of NF-κB [24,25].
These evidences suggest that integrin engagement can be a trigger to
the activation of signaling pathways known to modulate PMN sponta-
neous apoptosis. Recently, Ross and colleagues have shown that α9β1/
VCAM-1 interaction inhibits PMNs apoptosis [23]. However the mech-
anistic details underling this process was left understudied and, to our
knowledge, there is no detailed study on how α9β1 integrin-coupled
signaling pathways interact and how they converge to ﬁnally modulate
PMNapoptosis. In this regardwe sought to investigate themain signaling
events triggered by α9β1 integrin engagement and how these signaling
pathwaysmodulate the apoptotic program of human PMNs. To do sowe
used a recently described disintegrin, VLO5, isolated from Vipera lebetina
obtusa venom [31]. Disintegrins are a family of low molecular weight,
cysteine-richpeptidesusually isolated fromvipervenoms. Thesepeptides
are able to recognize and bindwith high afﬁnity to speciﬁc integrins [32].
They are usually single-chain polypeptides (monomeric disintegrins)
that express the Arg-Gly-Asp (RGD) motif within an amino acid hairpin
maintained by disulﬁde bridges [33]. VLO5 is a member of the recently
discovered group of dimeric disintegrins. VLO5 was shown to bind with
high afﬁnity to α4β1, α9β1 and α4β7 integrins, of which only α9β1 is
expressed in human PMNs. Our data demonstrate that α9β1 integrin
engagementdelayshumanPMNspontaneous apoptosis through thePI3K
and MAPK-Erk pathways. We also show that integrin engagement leads
to NF-κB nuclear translocation, upregulation of anti-apoptotic protein
Bcl-xL and degradation of pro-apoptotic protein Bad, whichmodulate the
mitochondrial apoptotic pathway in human PMNs.
2. Materials and methods
2.1. Reagents
Freeze-dried Vipera lebetina obtusa venom was purchased from
Latoxan Serpentarium (Rosans, France). VLO5 was puriﬁed from V. l.
obtusa venom as described [31]. Annexin V–FITC was purchased fromthe Laboratório de Biologia Celular e Molecular (Universidade de São
Paulo, SP, Brazil). RPMI-1640, 3,3-diaminobenzidine (DAB), N-formyl-
methionyl-leucyl-phenylalanine (fMLP), DNAse and protease inhibi-
tors were from Sigma-Aldrich. Anti-α9β1 integrin (clone Y9A2)
blocking antibody was from Chemicom International. Mouse mono-
clonal anti-actin, mouse monoclonal anti-phosphotyrosine, rabbit
polyclonal anti-FAK, rabbit polyclonal anti-p85 PI3K, rabbit polyclonal
anti-Erk-2, rabbit polyclonal anti-human NF-κB p65, rabbit polyclonal
anti-Bcl-xL, rabbit polyclonal rabbit polyclonal anti-Bax (Δ21), goat
polyclonal anti-cytochrome c, anti-αM integrin blocking antibody and
biotinilated donkey anti-goat IgG were from Santa Cruz Biotechnol-
ogy. Percoll, biotinilated donkey anti-rabbit or biotinilated sheep anti-
mouse IgGwere from Amersham Biosciences. LY294002 and PD98059
were from Calbiochem. HRP-conjugated streptavidin was from
Zymed.
2.2. Neutrophil isolation
PMNs were isolated from ethylenediaminetetraacetic acid (EDTA)
(0.5%)-treated peripheral venous blood from healthy human volun-
teers using a four-step discontinuous Percoll gradient as described
[34]. Residual erythrocytes were removed by hypotonic lysis. Isolated
PMNs were resuspended in RPMI supplemented with 10% heat-
inactivated FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin.
PMN viability and purity were always N99% and N97%, respectively.
2.3. Assessment of Neutrophil Apoptosis
2.3.1. Morphology
PMNs (1×106 cells/mL) were analyzed using cytospin prepara-
tions (6 min, 400 rpm) of fresh or 18 h (37 °C, 5% CO2) cultured cells.
PMNs were stained with Diff-Quik™ and counted under light
microscopy (×1000) to determine the proportion of cells showing
characteristic apoptotic morphology. At least 300 cells were counted
per slide. All experiments were performed at least in triplicate. The
results are expressed as mean±S D .
2.3.2. Annexin V binding assay
Phosphatidylserine exposure on apoptotic cell surface was ana-
lyzed by ﬂow cytometry. Fresh or 18 h cultured PMNs were incubated
with or without VLO5 (1 μM). Cells were then washed with binding
buffer (10 mMHepes (pH 7.4), 150 mMNaCl, 5 mM KCl, 1 mMMgCl2,
1.8mMCaCl2) and incubated for 20minwith 100 μL of AnnexinV–FITC
(2 μg/mL) working solution. After incubation cells were stained with
propidium iodide (PI, 100 μg/mL) for necrosis exclusion. PI and
AnnexinVbindingwere assessed on a FACSCaliburﬂowcytometer (BD
Biosciences) and analyzed using the CellQuest (BD Biosciences)
software. All experiments were performed at least in triplicate.
2.3.3. DNA fragmentation
PMNs (5×106 cells/mL) were incubated for 8 h at 37 °C in the
presence or absence of 1 μM VLO5. After incubation PMNs were lysed
in 500 μL of lysis buffer (0.2% Triton X-100, 1 mM EDTA, pH 7.4). Cell
lysates were then centrifuged at 13,000 g, and the supernatants
(containing fragmented DNA) were collected. Supernatants were
treated with 50 μL of 5 M NaCl and 500 μL of isopropanol and left for
12 h at−70 °C. DNA pellets were washed with 70% ethanol, air dried,
and resuspended in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.4).
Fragmented DNA was separated on a 1% agarose gel electrophoresis
containing 1 μg/mL ethidium bromide. The products of DNA
fragmentation were visualized and documented under UV light.
2.4. Immunoprecipitation
PMNs (5×106 cells/mL) were lysed in immunoprecipitation lysis
buffer (50 mM Tris–HCl, pH 7.4, 150 mMNaCl, 1.5 mMMgCl2, 1.5 mM
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leupeptin, 2 μg/μL pepstatin and 1 mM PMSF). Lysates (2 μg of
protein/μL) were incubated overnight at 4 °C with polyclonal anti-
FAK (1:200) antibody. Protein A/G agarose (20 μL/mg protein; Santa
Cruz Biotechnology) was then added, and samples were incubated at
4 °C on a shaker for 2 h. After incubation samples were centrifuged
and pellets were resuspended in sample buffer. Samples were
resolved on a 10% SDS-PAGE. FAK phosphorylation was assessed by
Western blot using anti-phosphotyrosine antibody (1:200) and
secondary polyclonal anti-mouse IgG (1:1000). Association of PI3K
to FAK was assessed by Western blot using anti-p85 PI3K antibody
(1:1000) and secondary polyclonal anti-IgG (1:1000).
2.5. Cellular nuclear extracts
PMNs (5×106 cells/mL) were lysed in ice-cold buffer A (10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT,
and 0.5mMPMSF). After a 15min incubation on ice, Nonidet P-40was
added to a ﬁnal concentration of 0.5% (v/v). After centrifugation
(1810×g; 5 min at 4 °C), pellet was suspended in ice-cold buffer C
(20 mMHEPES, pH 7.9, 400 mMNaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, 1 mM PMSF, 1 μg/mL pepstatin, 1 μg/mL leupeptin, and 20% (v/
v) glycerol) and incubated for 30 min at 4 °C. Supernatants containing
nuclear proteins were collected after centrifugation (12,000×g;
10 min at 4 °C). Samples were resolved on a 12% SDS-PAGE and
analyzed by Western blot using anti-human NF-κB p65 antibody
(1:1000), anti-histone H3 antibody (1:1000) or anti-Erk-2 antibody
(1:1000), and biotin-conjugated anti-rabbit IgG antibody (1:1000) or
biotin-conjugated anti-goat IgG antibody (1:1000).
2.6. Subcellular fractionation
Subcellular fractions were obtained as previously described [28].
Brieﬂy, PMNs (5×106 cells/mL)werewashed and resuspended in ice-
cold cytosol extraction buffer (250 nM sucrose, 70mMKCl, 250 μg/mL
digitonin, 10 μg/μL aprotinin, 10 μg/μL leupeptin, 2 μg/μL pepstatin
and 1 mM PMSF in PBS). After a 15 min incubation on ice, samples
were centrifuged at 1000× g for 5 min and supernatant was collected
(cytosolic fraction). Pellets were then resuspended in mitochondrial
lysis buffer (10 mM MgCl2, 2 mM EGTA, 2 mM EDTA, 1% Nonident P-
40 (v/v), 10% glycerol (v/v), 10 μg/μL aprotinin, 10 μg/μL leupeptin,
2 μg/μL pepstatin and 1 mM PMSF in 50 mM Tris, pH 7.5), incubated
for 10 min on ice and centrifuged at 10,000× g for 10 min.
Supernatant was taken as the mitochondrial fraction. Cytosolic and
mitochondrial fraction were resolved on a 15% SDS-PAGE and
analyzed by Western blot using anti-human cytochrome c antibody
(1:1000), anti-Bax (Δ21) antibody (1:1000) and secondary biotin-
conjugated anti-rabbit IgG antibody (1:1000).
2.7. Total cell extracts
PMNs (5×106 cells/mL)were incubatedwith VLO5 (1 μM) at 37 °C
in 5% CO2 atmosphere for the indicated times. To obtain the whole cell
extracts, cells were resuspended in lysis buffer (50mMHEPES, pH 6.4,
1 mM MgCl2, 10 mM EDTA, 1% Triton X-100, 1 μg/μL Dnase, 10 μg/μL
aprotinin, 10 μg/μL leupeptin, 2 μg/μL pepstatin and 1 mM PMSF) and
incubated for 30 min at 4 °C. The contents of Bad and Bcl-xL proteins
were analyzed by Western blotting as described bellow.
2.8. Western blotting analysis
The total protein content in samples was determined by the
Bradford's method [35]. Samples were denatured in sample buffer
(50 mM Tris–HCl, pH 6.8, 1% SDS, 5% 2-ME, 10% glycerol, and 0.001%
bromophenol blue) and boiled for 3 min. Samples (30 μg of total
protein) were resolved by SDS-PAGE and then transferred topolyvinylidenediﬂuoride (PVDF) membranes (Amersham Bios-
ciences). Membranes were blocked with T-TBS (20 mM Tris–HCl,
pH 7.5, 500 mM NaCl, 0.1% Tween 20) containing 1% BSA and probed
with the appropriate primary antibodies (1:1000). After extensive
washing in T-TBS, membranes were incubated with the appropriate
biotin-conjugated secondary antibodies (1:1000) for 1 h and then
incubated with HRP-conjugated streptavidin (1:1000) for a further
1 h. Immunoreactive bands were visualized by DAB staining. Image
capture was carried out using a HP PrecisionScan LTX and bands were
quantiﬁed by densitometry using ImageJ 1.34 s software (Wayne
Rasband, NIH, USA).
2.9. Determination of mitochondrial membrane potential (Δψm)
The change in mitochondrial membrane potential was measured
using the potentiometric dye JC-1 as described previously [36]. Brieﬂy,
PMNs (106 cells/mL) were incubated with VLO5 (1 μM) for 18 h at
37 °C. Cells were then incubated with 10 μg/mL JC-1 (Molecular
Probes) for 30 min at 37 °C. Suspensions were analyzed immediately
on a FACSCalibur ﬂow cytometer for red and green ﬂuorescence
(Becton Dickinson). Data analysis was carried out using CellQuest
software.
2.10. Statistical analysis
Statistical signiﬁcance was assessed by ANOVA, followed by
Bonferroni's t test, and pb0.05 was taken as statistically signiﬁcant.
3. Results
3.1. VLO5 delays neutrophil spontaneous apoptosis through an α9β1
integrin-dependent pathway
Adhesion to biological surfaces through cell adhesion molecules
is a powerful activator of PMN, being primarily modulated by
integrins. The integrin signaling pathways mediate important
functions in leukocytes, including apoptosis [2]. The ability of
VLO5 to modulate PMN spontaneous apoptosis was evaluated. As
shown in Fig. 1A, VLO5 was able to inhibit PMN spontaneous
apoptosis in a concentration-dependent manner as accessed
morphologically. This effect was dependent on VLO5 interaction
with α9β1 as it could be reverted by pre-treatment of the cells with
an anti-α9β1 monoclonal blocking antibody (clone Y9A2). To further
conﬁrm this data DNA fragmentation analysis and Annexin V
binding assay were preformed. VLO5 was able to prevent DNA
fragmentation observed after culturing cells for 8 h (Fig. 1B).
Moreover VLO5 inhibited phosphatidylserine exposure as accessed
by FACS analysis of Annexin V staining (Fig. 1C and D). Fig. 1C
shows histograms from one representative experiment, and Fig. 1D
shows means from four independent experiments. The effect of
VLO5 on phosphatidylserine exposure could be blocked by treat-
ment of cells with an anti-α9β1 blocking antibody (Fig. 1C and D).
Annexin V binding assay was performed in the presence of PI and
the proportion of cells undergoing necrosis was always lower than
3% (data not shown). Together these data suggest that VLO5 rescues
PMNs from spontaneous apoptosis through the interaction with
α9β1 integrins.
3.2. Activation of integrin-coupled signaling pathways by VLO5 in
human neutrophils
Integrin activation triggers autophosphorylation and activation of
FAK that converts FAK into a docking site for PI3K activation. Activated
PI3K is able to regulate several cellular processes such as migration,
adhesion and apoptosis [13]. We then sought to investigate whether
VLO5 could trigger the activation of this integrin-coupled signaling
Fig. 1. VLO5 inhibit PMN spontaneous apoptosis. (A) Cells were pretreated for 5 min at 37 °C with medium alone (black and gray bars) or with the anti-α9β1 blocking antibody
(10 μg/mL, open bars) followed by incubation for 0 and 18 h at 37 °C in the absence (−) or presence of VLO5 (0 .01–1 μM). The number of apoptotic cells was assessed by cytology on
cytocentrifuge preparations as described in Section 2. Data represent the means±SD of at least 300 cells from four independent experiments. (B) Cells (5×106 cells) were incubated
with RPMImedium (lane 3) or VLO5 (1 μM, lane 4) for 8 h, and then internucleossomal DNA fragmentation was determined as described in Section 2. Lane 2 represents nonapoptotic
fresh PMNs, and lane 1 represents a molecular weight marker (kb). (C and D) Cells were pretreated for 5 min at 37 °C with medium alone or with the anti-α9β1 blocking antibody
followed by incubation for 0 and 18 h at 37 °C in the absence (Control 0 h, black bar and 18 h, gray bar) or presence of VLO5 (1 μM, VLO5, open bar and VLO5 + anti-α9β1, light gray
bar). The percentage of Annexin V-positive cells in each sample is indicated. C shows histograms from one representative experiment, and D shows means±SD from four
independent experiments. ⁎Pb0.05 compared to cells incubated for 18 h with medium alone or VLO5 + anti-α9β1.
851R.F. Saldanha-Gama et al. / Biochimica et Biophysica Acta 1803 (2010) 848–857pathway in PMNs. Using immunoprecipitation and Western blotting
analysis we could observe that VLO5 was able to induce FAK
phosphorylation (Fig. 2A) and FAK–PI3K association (Fig. 2B).
Activation of FAK–PI3K through integrin signaling triggers the
activation of the Ras–Raf–MAPK pathway leading to Erk-2 phosphor-
ylation and subsequent nuclear translocation [16]. VLO5 was able to
induce the translocation of Erk-2 to the nucleus in a PI3K-dependent
manner as this effect could be blocked by the treatment of cells with
the PI3K inhibitor LY294002.We could also block the effect of VLO5 on
Erk1/2 nuclear translocation by the treatment of cells with anti-α9β1
integrin blocking antibody (Fig. 2C). These data suggest that VLO5,
interacting with α9β1 integrin triggers integrin-coupled signaling
pathways in PMNs.3.3. VLO5 inhibition of neutrophil spontaneous apoptosis is dependent
on PI3K and MAPK pathways
Activation of FAK-PI3K and MAPK pathways is known to inhibit
apoptosis in several experimental settings and different cell types
[37]. We tested whether the effects of VLO5 on PMN spontaneous
apoptosis could be attributed to the activation of integrin-coupled
signaling pathways. Pre-incubation of cells with PI3K inhibitor
LY294002 or the MEK 1/2 inhibitor PD98059 reverted the VLO5
effect on PMN spontaneous apoptosis (Fig. 3A). As expected, PD98059
was able to inhibit Erk activation, as measured by Erk nuclear
translocation (Fig. 3B) and LY294002 efﬁciently inhibited the
activation of the PI3K downstream target, Akt, as measured by Akt
Fig. 2. VLO5 activates integrin-coupled signaling pathways in PMNs. (A and B) PMNs
were treated with VLO5 (1 μM, gray bar) or medium (white bar) for 5 min at 37 °C, and
immunoprecipitation was carried out as described in methods using an anti-FAK
antibody. Samples were analyzed using an anti-phosphotyrosine antibody for p-FAK
(A) and p85 PI3K (B), and total FAK was used as loading control for both samples. FAK
phosphorylation and PI3K/FAK association were determined by immunoblotting and
quantiﬁed by densitometry. (C) PMNs were pretreated for 5 min at 37 °C with medium
alone or with LY294002 (3 μM), or with an anti-α9β1 blocking antibody (10 μg/mL)
followed by incubation for 1 h at 37 °C in the absence (white bar) or presence of VLO5
(1 μM, gray, black and dashed bars). Erk-2 nuclear content was determined by
immunoblotting using an anti-Erk-2 antibody and quantiﬁed by densitometry. Data
shows means±SD of three similar experiments. ⁎Pb0.05 compared with control cells
or compared with LY294002 and (C) anti-α9β1 pretreated cells.
Fig. 3. Involvement of PI3K andMAPK pathways on the anti-apoptotic effects of VLO5. (A)
Cells were pretreated for 5min at 37 °Cwithmedium alone (open bars), PD98059 (10 μM,
light gray bars) or LY294002 (3 μM,dark gray bars) followedby incubation for 18 h at 37 °C
in theabsence (Ctrl) or in thepresenceof VLO5(VLO5, 1 μM). Thenumberof apoptotic cells
was assessed by cytology on cytocentrifuge preparations as described in materials and
methods. Data represent means±SD of at least 300 cells from three independent
experiments. ⁎Pb0.05 compared with control cells or compared with PD98059 and
LY294002 pretreated cells. (B) Erk nuclear translocation in unstimulated PMNs (Ctrl),
PMNs treated with VLO5 (VLO5) or VLO5 plus PD98059 (VLO5+PD). (C) Akt
phosphorylation in unstimulated PMNs (Ctrl), PMNs treated with VLO5 (VLO5) or VLO5
plus LY294002 (VLO5+LY). Blots in B and C are from one representative out of three
independent experiments. Graphs in B and C are the means±SD of three independent
experiments. ⁎ Represents signiﬁcant differences relative to VLO5-stimulated PMNs.
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no effect on the apoptosis of unstimulated PMNs (Fig. 3A).
3.4. VLO5 interferes with the mitochondrial apoptotic pathway
PMN spontaneous apoptosis involves the mitochondrial pathway
which is triggered by the translocation of pro-apoptotic proteins such
as Bax to the mitochondrial outer membrane. This leads to the
dissipation of mitochondrial membrane potential (Δψm) and cyto-chrome c release which in turn triggers the formation of the
apoptosome and the activation of caspase-9 and -3 [30]. To measure
the Δψm we used the potentiometric dye JC-1 (5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide). JC-1 exists as
a monomer in the cytosol (green) and also accumulates as J
aggregates in the mitochondria which stains red. On the other hand,
in apoptotic cells mitochondrial membrane potential collapses and JC-
1 does not accumulate as red aggregates in the mitochondria.
Consequently apoptotic cells stain primarily green and can then be
easily differentiated from healthy cells showing green and red
staining [38]. As can be seen in Fig. 4, PMNs incubated for 18 h
presented low red to green ratio, indicating Δψm dissipation. VLO5
inhibited the dissipation of mitochondrial membrane potential
increasing the ratio of red to green ﬂuorescence intensity in ﬂow
cytometry analysis (Fig. 4, right panel). This effect was shown to be
dependent on VLO5 and α9β1 integrin interaction as it could be
blocked by the anti-α9β1 blocking antibody (Fig. 4). Dot-plot analysis
Fig. 4. Effect of VLO5 on mitochondrial membrane potential (Δψm). PMNs were pretreated for 5 min at 37 °C with medium alone (light gray and open bars) or with anti-α9β1
blocking antibody (10 μg/mL, dark gray bar) followed by incubation for 18 h at 37 °C in absence (Cont 18 h) or in the presence of VLO5 (1 μM, VLO5 and VLO5 + α9β1). Fresh PMNs
(Cont 0 h, black bar) were used as control of mitochondrial membrane integrity. Cells were stained with 5 μg/mL of JC-1 dye for 30 min at 37 °C and analyzed by ﬂow cytometry. The
Δψmperturbation was determined by taking the ratio of mean ﬂuorescence intensities of red to green ﬂorescence. Dot plots (left panel) are from one representative experiment and
show the percent of double positive cells in fresh PMNs (ctrl 0 h), PMNs incubated for 18 h (ctrl 18hs), PMNs treated with VLO5 for 18 h (VLO5), and PMNs treated for 18 hwith VLO5
plus anti-α9β1 blocking antibody (VLO5 + anti-α9β1). ⁎Pb0.05 compared to cells incubated for 18 h with medium alone or VLO5 + anti-α9β1.
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single green positivity cells while Δψm dissipation (or apoptosis) is
represented by a shift to double-positive. As can be seen in Fig. 4 (left
panel), PMNs incubated for 18 h present an increase in the percent ofFig. 5. Effects of VLO5 on Bax mitochondrial content and cytochrome c release to the cytosol.
bars) for 0 and 18 h at 37 °C. PMN lysates were prepared by subcellular fractionation and cyto
and mitochondrial fractions were immunoblotted. (A) The samples were analyzed using ant
analyzed using anti-cytochrome c antibody, and mitochondrial/cytosol cytochrome c ratiodouble-positive cells (viable cells) relative to freshly isolated PMNs,
indicating increased Δψm dissipation. This could be reverted by
incubation with VLO5. Consistently anti-α9β1 blocking antibody
inhibited the effects of VLO5.(A and B). PMNs were treated with VLO5 (1 μM, gray bar) or medium (white and black
solic, andmitochondrial fractions were obtained as described inmethods. The cytosolic
i-Bax antibody, and a cytosol/mitochondrial Bax ratio was obtained. (B) Samples were
was obtained. ⁎Pb0.05 compared to cells incubated for 18 h.
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apoptotic proteins, such as Bax, to the mitochondrial membrane. This is
an event that initiates early in apoptosis and increases throughout the
process, being well detected in later time points [69]. Using subcellular
fractionation we could further demonstrate that VLO5 was able to
inhibit the translocation of pro-apoptotic protein Bax to the mito-
chondria (Fig. 5A) and cytochrome c release to the cytosol (Fig. 5B).
3.5. VLO5 induces NF-κB translocation to the nucleus
Activation of PI3K can lead to the activation of the Akt pathway
which in turn can induce NF-κB nuclear translocation. NF-κB nuclear
translocation triggers the expression of several target genes including
the anti-apoptotic genes Bcl-2 and Bcl-xL [21-25]. We showed that
the anti-apoptotic effect of VLO5 was dependent on PI3K activation
(Fig. 3). We then sought to investigate whether VLO5 could induce
NF-κB nuclear translocation. As shown in Fig. 6, VLO5 increased NF-κB
nuclear content relative to control. This effect was dependent on VLO5
interaction with α9β1 as it could be reverted by pre-treatment of the
cells with an anti-α9β1 blocking antibody.
3.6. VLO5 promotes Bcl-xL expression and Bad degradation
It is well demonstrated that activation of PI3K/Akt pathway results
in a rescue from apoptosis bymodulation of the balance between anti-
and pro-apoptotic proteins in PMNs. PI3K/Akt pathway activation in
PMNs results in Bad phosphorylation and proteasome-dependent
degradation. This is a relatively rapid process that can be detected
within 30 minutes. Akt activation also results in increased expression
of the anti-apoptotic protein Bcl-xL. This process depends on protein
synthesis and is detected in later time points (2 and 4 h) [58]. We
tested whether VLO5 could modulate the balance between anti- and
pro-apoptotic proteins in PMNs. As shown in Fig. 7, VLO5 treatment
diminished cellular content of the pro-apoptotic protein Bad (Fig. 7A)Fig. 6. Effect of VLO5 on NF-κB nuclear translocation. . PMNs were pretreated for 5 min
at 37 °C with medium alone (open and gray bars) or with anti-α9β1 blocking antibody
(black bar) followed by incubation with VLO5 (1 μM, gray and black bars) or medium
(open bar) for 90 min at 37 °C. Nuclear fractions were obtained as described in
methods. Samples were separated on SDS-PAGE and immunoblotted for the detection
of NK-κB p65 subunit. Histone H3 content was used as loading control. Immunoblot
ﬁgures are one representative out of three independent experiments. Graphs show
means±SD of bands intensity (arbitrary units) and ⁎ indicates signiﬁcant difference
compared to control or compared with anti-α9β1 pretreated cells.
Fig. 7. Effect of VLO5 on total cellular content of Bad and Bcl-xL. PMNs were pretreated
for 5 min at 37 °C with medium alone (open and gray bars) or with anti-α9β1 blocking
antibody (black bar) followed by incubation with VLO5 (1 μM, gray and black bars) or
medium (white bar) for the indicated times at 37 °C. Samples were subjected to SDS-
PAGE and total Bad (A) or Bcl-xL (B) content were evaluated by western blotting. Actin
content was used as loading control. Immunoblot ﬁgures are one representative out of
three independent experiments. Graphs showmeans±SD of bands intensity (arbitrary
units) and ⁎ indicates signiﬁcant difference compared to control or comparedwith anti-
α9β1 pretreated cells.and increased the content of the anti-apoptotic protein Bcl-xL (Fig. 7B).
The effect of VLO5 on Bad content was dependent on the engagement
ofα9β1 integrin since pre-treatmentwith anti-α9β1 blocking antibody
could prevent the decrease in total Bad content. Taken together these
data suggest that VLO5 modulates the mitochondrial apoptotic
pathway in PMNs by increasing the anti- to pro-apoptotic protein
ratio. This would inhibit pro-apoptotic protein translocation to the
mitochondrial membrane, prevent the dissipation of mitochondrial
membrane potential and cytochrome c release to the cytosol.
4. Discussion
PMN apoptosis is a critical cellular process that modulates PMN
number and function playing an essential role in PMN homeostasis
855R.F. Saldanha-Gama et al. / Biochimica et Biophysica Acta 1803 (2010) 848–857and resolution of inﬂammation [39,40]. PMN lifespan can be extended
by several stimuli including cytokines, growth factors, bacterial
products [1]. Moreover PMN viability can be modulated by other
molecular cues derived from the surrounding environment which
include adhesion molecules expressed by endothelial cells and ECM
proteins [1,2,41]. These factors are usually encountered en route and in
situ during inﬂammatory conditions, and contribute to the mainte-
nance of viable and fully functional PMNs at the site of inﬂammation.
PMNs express a large set of integrins including those constitutively
expressed and those expressed upon activation [4]. TheαMβ2 integrin
is the most abundant integrin expressed by PMNs and therefore is the
target of many studies addressing the potential modulatory role of
integrin engagement on PMN function and viability [41]. The relative
contribution of other integrins remains underinvestigated even
though the possibility that their contribution as modulators of PMN
functions can also be relevant.
In this sense α9β1 integrin appears as a potentially important
modulator of PMN function and viability. Expression of α9β1 can be
upregulated upon activation and it is a natural ligand for endothelial
cell-expressed adhesion molecules and ECM-derived proteins. This
implies that α9β1 integrin engagement is likely to occur during all
phases of PMN activity and thereforemay contribute to the arrival and
maintenance of long-lived tissue PMNs. Despite this the role of α9β1
integrin as a modulator of PMN life span remains poorly studied. Ross
and cols. have recently demonstrated that VCAM-1 inhibits PMN
spontaneous apoptosis through the interaction with α9β1 [23]. The
molecular mechanisms involved in this process however were only
superﬁcially addressed and remained largely unknown. In the present
study we evaluated the effects of α9β1 integrin engagement on PMN
apoptosis and the signaling pathways involved in this process. To do
so we used a snake venom-derived disintegrin, VLO5, that binds to
α9β1, α4β1, and α4β7 integrins. We demonstrated that α9β1/VLO5
interaction potently inhibited PMN spontaneous apoptosis through
the activation of integrin-coupled signaling pathways.
In our preliminary experiments, we could not detect signiﬁcant
expression of α4β1 integrin by resting PMNs (Supplementary Fig. 1),
which is consistent with previous reports [23]. Other groups reported
a low expression of α4β1 integrin by resting PMNs that could be
upregulated upon stimulation [70, 71]. However we could not detect
signiﬁcant expression of α4β1 integrin by VLO5-stimulated PMNs
(Suppl Fig. 1). On the other hand PMNs substantially expressed the
integrin α9β1 (Supplementary Fig. 1). Based on these results, we
assumed that PMNs only express α9β1 integrin among the three
potential VLO5 ligands, and that the effects of VLO5 on PMNs were a
consequence of α9β1 engagement. This assumption found further
support by the block of VLO5 effects when we used an anti-α9β1
blocking antibody.
Initially described as potent antagonists of integrins deprived of
intrinsic agonistic activity [42,43], disintegrins have recently been
shown to interact with and activate integrin signaling pathways in
some cell types [34,44,45]. These studies expanded the applications of
disintegrins as tools for studying integrin biology demonstrating that
these proteins can be used as integrin antagonists or integrin
activators depending on the cell type investigated. Here we
demonstrate that VLO5 can activate integrin-coupled signaling path-
ways on PMNs and that this effect could be blocked by co-incubation
with blocking anti-α9β1 integrin antibody. This suggests that VLO5
can be used as an α9β1 integrin activator in PMN.
Recently our group demonstrated that the EC3 disintegrin
interacts with and activates α9β1 integrin in PMN but, in contrast to
the observed inhibitory effect of VLO5, EC3 accelerated PMN apoptosis
[46]. EC3 and VLO5 are heterodimeric disintegrins that present the
Val-Gly-Asp (VGD)motif on its A-subunit and theMet-Leu-Asp (MLD)
tripeptide in the B-subunit. The ligand selectivity and biological effects
of EC3 and VLO5 has been attributed to the MLD sequence [47,48]
while their differential effects have been attributed to amino acidssurrounding the active MLD motif. Sequence analysis pointed to a
single amino acid replacement N-terminally to the MLD motif: EC3
presenting an alanine and VLO5 a threonine (CKRAMLDGNDYC-EC3
and CKRTMLDGLNDYC-VLO5) [48]. Using synthetic peptides the
authors demonstrated that VLO5 is a more potent inhibitor for
α9β1/VCAM-1 interaction than EC3, conﬁrming data obtained for the
native disintegrins [48]. The replacement of an apolar (alanine) by a
polar (threonine) amino acid could result in the differential afﬁnities
observed that could explain their different biological effects despite
the same speciﬁcities. Altogether these data suggest that when using
disintegrins as tools for studying integrin biology it must be taken into
account the cell type used and the nature of the interaction between
the disintegrin and its cognate integrin.
VLO5 effects on PMN apoptosis were similar to those found using
the natural α9β1 integrin ligand VCAM-1 [23 and personal observa-
tion]. This suggests that VLO5 treatment mimics the events triggered
in vivo by α9β1 integrin engagement in PMNs. We focused on the
effects of α9β1 integrin engagement on PMN survival and demon-
strate that VLO5 inhibited PMN spontaneous apoptosis through the
activation of integrin-coupled signaling events.
FAK phosphorylation is pivotal to integrin-mediated signaling
since this cytoplasmatic tyrosine kinase acts as a scaffold for several
effector molecules such as Src, PI3K and the Ras/Raf/MAPK cascades
[37,49]. FAK activation has been associated with survival signals due
to the activation of the PI3K and the Ras/Raf/MAPK pathways [37,50-
52]. Upon activation PI3K activates protein kinase B (Akt), which is
intimately involved in apoptosis resistance, regulating the activity of
several Bcl-2 family members [37,53-56].
We demonstrate that VLO5 induces FAK phosphorylation and
PI3K-FAK association in PMNs. Moreover the delay in PMN sponta-
neous apoptosis triggered by VLO5 was dependent on PI3K activation.
This adds new information to previous work by Ross and colleagues
demonstrating that the inhibitory effect of VCAM-1 on PMN apoptosis
was dependent on PI3K activation [23]. Furthermore we demonstrate
that VLO5 induces Erk nuclear translocation and this effect is
dependent on PI3K activation. The triggering of several intracellular
signaling pathways linked to FAK and PI3K activation includes Ras/
Raf-dependent Erk activation. Erk, a MAPK family member, is
activated by tyrosine phosphorylation and translocates to the nucleus,
affecting gene expression by directly phosphorylating transcription
factors [57]. The MAPK pathway can control several PMN functions
including cell survival [58-60].
PMN spontaneous apoptosis generally involves the intrinsic
mitochondrial pathway. In fact the few mitochondria presented by
PMNs appear to be sole modulators of PMN life span, having no
apparent role in other PMN functions [28]. This intrinsic apoptotic
pathway involves the translocation of pro-apoptotic proteins to the
mitochondrial outer membrane and dissipation of mitochondrial
membrane potential. These events lead to the leakage of cytochrome c
to the cytosol and activation of the apoptosome, culminating in
caspase-3 activation and apoptosis [61]. After 18 h of incubation a loss
of mitochondrial transmembrane potential can be observed sugges-
tive of a disruption of the outer membrane integrity and release of
mitochondrial content into the cytosol. Activation of α9β1 integrin
signaling by VLO5 inhibits this process, preserving the transmem-
brane potential and consequently inhibits apoptosis. This effect seems
to involve the modulation of cellular localization of the pro-apoptotic
protein Bax, as VLO5 maintains Bax in the cytosol and prevents its
translocation to the mitochondrial membrane. This consequently
inhibits pore formation and cytochrome c release into the cytosol.
Different events can be involved in the cytosolic sequestration of
pro-apoptotic proteins and consequent inhibition of apoptosis.
Activation of the PI3K/Akt and the Ras/Raf/MAPK pathways can
lead to Bad phosphorylation at speciﬁc serine residues. Phosphory-
lated Bad binds to 14-3-3ζ proteins in the cytosol that sequesters and
tags Bad for subsequent degradation [62]. Alternatively, pro-apoptotic
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proteins as Bcl-2 and Bcl-xL [63]. We observed Bad degradation
triggered by α9β1 integrin activation in PMNs. This could be a
consequence of PI3K/MAPK-dependent Bad phosphorylation and 14-
3-3ζ-dependent degradation. On the other hand, we also found an
increased expression of the anti-apoptotic protein Bcl-xL. In fact
activation of the PI3K/Akt pathway was shown to increase Bcl-xL
transcription through NF-κB activation [64,65]. In this regardwe show
that VLO5 induces NF-κB nuclear translocation accompanied by
increased Bcl-xL expression. Similarly Ross and cols. previously
reported an α9β1/VCAM-1-dependent NF-κB activation in PMNs
[23]. This could increase the intracellular anti-/pro-apoptotic protein
ratio and account for the inhibition of PMN apoptosis. Based in the
above ﬁndings we may speculate that both 14-3-3ζ- and NF-κB-
dependent processes can be operational in our system and both may
respond to the anti-apoptotic effects of α9β1 integrin engagement.
The molecular mechanisms triggered by α9β1 integrin engage-
ment that culminates in delayed PMN apoptosis resemble those
described for other modulators of PMN life-span such as cytokines
and growth factors. For example, granulocyte-macrophage-colony
stimulating factor (GM-CSF)-inhibition of PMN apoptosis involves the
activation of PI3K and MAPK pathways [66,67]. This suggests that
cytokines, growth factors, integrins and other modulators of PMN
survival can sum and potentiate their effects to maintain long-lived,
functional PMNs in tissues. In fact it was recently demonstrated that
granulocyte-colony stimulating factor (G-CSF) signaling can be
enhanced by α9β1 integrin signaling in PMNs [68]. However, how
these factors cooperate in order to reach this goal in pathophysiolog-
ical settings needs more profound studies.
5. Conclusion
By using the snake venom-derived disintegrin, VLO5, we could
systematically study the role of α9β1 integrin signaling in PMN
survival. We provide strong evidences and detailed molecular
mechanisms for the modulation of PMN spontaneous apoptosis by
α9β1 integrin engagement. This study has at least two important
implications: (i) the detailed understanding of the mechanisms
involved in the control of PMN life-span may provide potential
targets for future therapies for diseases where PMNs play a
determinant role; and (ii) snake venom disintegrins are suitable
tools for the study of integrin biology and can be a potential template
for the design of integrin modulating agents.
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